Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1

Interventions

trametinib 6dabrafenib 6pembrolizumab 5lenvatinib 5Paclitaxel 5Sorafenib 4Radiotherapy, Intensity-Modulated 3Doxorubicin 3pazopanib 2atezolizumab 2aldesleukin 2Taxes 2Radiotherapy 2Nivolumab 2Everolimus 2Bevacizumab 2zimberelimab 1selpercatinib 1sargramostim 1sacituzumab govitecan 1fosbretabulin 1fludarabine 1efatutazone 1cobimetinib 1ceritinib 1cemiplimab 1cabozantinib 1abemaciclib 1Vemurafenib 1Tamoxifen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Thyroid Carcinoma, Anaplastic × CUDC-907 × Clear all
NCT03002623 2018-12-21

CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
7 enrolled 13 charts
EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡